Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (1037)	7/25/1997 7:38:00 PM
From: biopicker	of 6136

John-- As far as specific predictions as to where Agouron will go with short covering, I do not know. What I do know is I would hate to be in a position of buying back 3.5 million shares of stock of a thinly capitalized company whose fundamentals appear to be exploding. On another subject, Brown Brothers analyst Robert Leboyer today put out comments in response to The Wall Street Journal's article yesterday ("Die Hard Short Sellers"), he refuted all points made in the article. Concerning the side effect of diarrhea he stated "clinicians with whom he spoke were unanimous in saying that diarrhea is not a factor and that it is controlled with over-the-counter medications. Further, he said "Little Agouron is marketing its drug with a sales force dedicated only to Viracept." This sales force is experienced and as large as the antiviral units of the larger drug companies. Furthermore, Aids patients are unusually well informed about Viracept's efficacy data, dosing, and side effect profile which all compare favorably with its competititors. He said much more, but the bottom line is buy ahead of what he expects to be a very positive earnings report. Next week should be a very exciting one. Cheers to All! Biopicker

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next